Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

206.72 +1.97 (+0.96%)

Streaming Delayed Price Updated: 3:31 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone ↗

January 22, 2025

The CNN Business Fear & Greed Index measures market sentiment, with higher fear putting pressure on stocks.

Via Benzinga

Topics Government Stocks

Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday ↗

January 22, 2025

Via Benzinga

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

January 22, 2025

Via Benzinga

Big Trading Day Ends With Q4 Earnings Beats: NFLX, UAL, COF ↗

January 21, 2025

Markets had a strong session on the first full day of President Trump’s second administration. Indexes have rocketed up from 2025 lows hit a week to a week and a half ago.

Via Talk Markets

Topics Government Stocks / Equities

Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse? ↗

January 21, 2025

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside

Via Benzinga

Looking Into Johnson & Johnson's Recent Short Interest ↗

January 14, 2025

Via Benzinga

Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'? ↗

January 21, 2025

Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the key items and numbers to watch.

Via Benzinga

Topics Stocks

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression ↗

January 21, 2025

FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)

January 21, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. ↗

January 21, 2025

Via The Motley Fool

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever ↗

January 21, 2025

Via The Motley Fool

Healthcare And Biotech Stocks Lag The Market Again ↗

January 20, 2025

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Via Talk Markets

Topics Stocks / Equities

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals.

Via Benzinga

MarketBeat Week in Review – 01/13 - 01/17

January 18, 2025

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

Via MarketBeat

Topics Economy Energy

3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond ↗

January 18, 2025

Via The Motley Fool

Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade ↗

January 18, 2025

This magnificent company has been paying a continuous dividend to its shareholders since 1816.

Via The Motley Fool

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

January 17, 2025

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

Via MarketBeat

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

January 17, 2025

These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors.

Via The Motley Fool

10 One Decision Stocks To Buy Now ↗

January 15, 2025

The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats.

Via Talk Markets

Topics Stocks / Equities

Got $200? 2 Dividend Stocks to Buy and Hold Forever ↗

January 15, 2025

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

Via The Motley Fool

What Lies Ahead In 2025? Slower Growth, More Volatility ↗

January 14, 2025

As we move through 2025, the global economy and financial markets are facing a critical juncture.

Via Talk Markets

Topics Economy Stocks / Equities

Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty ↗

January 14, 2025

ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts and biotech recovery delays.

Via Benzinga

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On? ↗

January 13, 2025

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)

January 13, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗

January 13, 2025

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.

Via Benzinga

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal ↗

January 13, 2025

The deal values the smaller biotech company at a 39% premium to last week's closing price.

Via Investor's Business Daily

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions